Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This paper was supported, in part, by the US Department of Veterans Affairs. M Hoffman has received research funding in the past 5 years from Novo Nordisk, CSL Behring & Boehringer-Ingelheim. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.